Cidara Therapeutics, Inc. Logo

Cidara Therapeutics, Inc.

CDTX

(0.5)
Stock Price

12,01 USD

-48.37% ROA

-264.84% ROE

-2.27x PER

Market Cap.

69.643.069,00 USD

54.21% DER

0% Yield

-55.49% NPM

Cidara Therapeutics, Inc. Stock Analysis

Cidara Therapeutics, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Cidara Therapeutics, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock maintains a fair debt to equity ratio (54%), indicating a reasonable balance between the money it owes and the ownership it possesses.

2 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

3 ROE

Negative ROE (-259.13%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-48.37%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 PBV

The stock's high Price-to-Book Value (P/BV) ratio (8.76x) suggests it's overvalued, potentially making it an expensive investment.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-1) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Cidara Therapeutics, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Cidara Therapeutics, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

Cidara Therapeutics, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Cidara Therapeutics, Inc. Revenue
Year Revenue Growth
2013 0
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 20.915.000 100%
2020 12.067.000 -73.32%
2021 49.572.000 75.66%
2022 64.288.000 22.89%
2023 50.872.000 -26.37%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Cidara Therapeutics, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2013 810.000
2014 6.710.000 87.93%
2015 23.475.000 71.42%
2016 35.699.000 34.24%
2017 42.823.000 16.64%
2018 49.142.000 12.86%
2019 46.401.000 -5.91%
2020 68.017.000 31.78%
2021 73.087.000 6.94%
2022 75.520.000 3.22%
2023 69.320.000 -8.94%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Cidara Therapeutics, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 272.000
2014 3.306.000 91.77%
2015 8.838.000 62.59%
2016 12.737.000 30.61%
2017 12.898.000 1.25%
2018 14.143.000 8.8%
2019 16.238.000 12.9%
2020 15.899.000 -2.13%
2021 18.740.000 15.16%
2022 18.486.000 -1.37%
2023 14.224.000 -29.96%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Cidara Therapeutics, Inc. EBITDA
Year EBITDA Growth
2013 -1.082.000
2014 -8.230.000 86.85%
2015 -32.313.000 74.53%
2016 -48.436.000 33.29%
2017 -55.721.000 13.07%
2018 -67.136.000 17%
2019 -42.135.000 -59.34%
2020 -71.620.000 41.17%
2021 -42.255.000 -69.49%
2022 -29.718.000 -42.19%
2023 -34.220.000 13.16%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Cidara Therapeutics, Inc. Gross Profit
Year Gross Profit Growth
2013 0
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 20.915.000 100%
2020 12.067.000 -73.32%
2021 49.572.000 75.66%
2022 64.288.000 22.89%
2023 49.324.000 -30.34%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Cidara Therapeutics, Inc. Net Profit
Year Net Profit Growth
2013 -1.344.000
2014 -11.894.000 88.7%
2015 -32.193.000 63.05%
2016 -48.165.000 33.16%
2017 -55.728.000 13.57%
2018 -59.016.000 5.57%
2019 -40.085.000 -47.23%
2020 -72.373.000 44.61%
2021 -43.909.000 -64.82%
2022 -29.799.000 -47.35%
2023 -32.688.000 8.84%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Cidara Therapeutics, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 0
2014 -1 0%
2015 -3 100%
2016 -3 0%
2017 -3 0%
2018 -2 -50%
2019 -1 -100%
2020 -2 0%
2021 -1 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Cidara Therapeutics, Inc. Free Cashflow
Year Free Cashflow Growth
2013 -1.048.000
2014 -8.701.000 87.96%
2015 -27.129.000 67.93%
2016 -40.172.000 32.47%
2017 -50.215.000 20%
2018 -56.882.000 11.72%
2019 -28.567.000 -99.12%
2020 -54.597.000 47.68%
2021 -25.273.000 -116.03%
2022 -28.591.000 11.61%
2023 3.849.000 842.82%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Cidara Therapeutics, Inc. Operating Cashflow
Year Operating Cashflow Growth
2013 -1.048.000
2014 -7.710.000 86.41%
2015 -25.959.000 70.3%
2016 -39.771.000 34.73%
2017 -49.909.000 20.31%
2018 -56.705.000 11.98%
2019 -28.532.000 -98.74%
2020 -54.411.000 47.56%
2021 -25.232.000 -115.64%
2022 -28.473.000 11.38%
2023 3.849.000 839.75%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Cidara Therapeutics, Inc. Capital Expenditure
Year Capital Expenditure Growth
2013 0
2014 991.000 100%
2015 1.170.000 15.3%
2016 401.000 -191.77%
2017 306.000 -31.05%
2018 177.000 -72.88%
2019 35.000 -405.71%
2020 186.000 81.18%
2021 41.000 -353.66%
2022 118.000 65.25%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Cidara Therapeutics, Inc. Equity
Year Equity Growth
2013 -1.398.000
2014 21.103.000 106.62%
2015 103.912.000 79.69%
2016 88.179.000 -17.84%
2017 59.744.000 -47.59%
2018 59.139.000 -1.02%
2019 37.835.000 -56.31%
2020 10.715.000 -253.1%
2021 21.573.000 50.33%
2022 -2.904.000 842.87%
2023 8.038.000 136.13%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Cidara Therapeutics, Inc. Assets
Year Assets Growth
2013 201.000
2014 24.350.000 99.17%
2015 109.974.000 77.86%
2016 106.962.000 -2.82%
2017 79.035.000 -35.33%
2018 79.112.000 0.1%
2019 68.976.000 -14.69%
2020 60.424.000 -14.15%
2021 75.325.000 19.78%
2022 47.593.000 -58.27%
2023 63.468.000 25.01%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Cidara Therapeutics, Inc. Liabilities
Year Liabilities Growth
2013 1.599.000
2014 3.247.000 50.75%
2015 6.062.000 46.44%
2016 18.783.000 67.73%
2017 19.291.000 2.63%
2018 19.973.000 3.41%
2019 31.141.000 35.86%
2020 49.709.000 37.35%
2021 53.752.000 7.52%
2022 50.497.000 -6.45%
2023 55.430.000 8.9%

Cidara Therapeutics, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.63
Net Income per Share
-0.34
Price to Earning Ratio
-2.27x
Price To Sales Ratio
1.23x
POCF Ratio
-2.76
PFCF Ratio
-2.74
Price to Book Ratio
8.65
EV to Sales
0.45
EV Over EBITDA
-0.8
EV to Operating CashFlow
-1
EV to FreeCashFlow
-1
Earnings Yield
-0.44
FreeCashFlow Yield
-0.37
Market Cap
0,07 Bil.
Enterprise Value
0,03 Bil.
Graham Number
0.83
Graham NetNet
-0.04

Income Statement Metrics

Net Income per Share
-0.34
Income Quality
1.31
ROE
-2.59
Return On Assets
-0.49
Return On Capital Employed
-1.14
Net Income per EBT
1.04
EBT Per Ebit
0.95
Ebit per Revenue
-0.56
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0.26
Research & Developement to Revenue
1.3
Stock Based Compensation to Revenue
0.05
Gross Profit Margin
0.98
Operating Profit Margin
-0.56
Pretax Profit Margin
-0.53
Net Profit Margin
-0.55

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.28
Free CashFlow per Share
-0.28
Capex to Operating CashFlow
0.01
Capex to Revenue
-0
Capex to Depreciation
-0.56
Return on Invested Capital
-1.92
Return on Tangible Assets
-0.48
Days Sales Outstanding
18.43
Days Payables Outstanding
3452.88
Days of Inventory on Hand
2326.76
Receivables Turnover
19.8
Payables Turnover
0.11
Inventory Turnover
0.16
Capex per Share
-0

Balance Sheet

Cash per Share
0,54
Book Value per Share
0,09
Tangible Book Value per Share
0.09
Shareholders Equity per Share
0.09
Interest Debt per Share
0.06
Debt to Equity
0.54
Debt to Assets
0.07
Net Debt to EBITDA
1.4
Current Ratio
1.62
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0.54
Working Capital
0,02 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
2210500
Debt to Market Cap
0.06

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Cidara Therapeutics, Inc. Dividends
Year Dividends Growth

Cidara Therapeutics, Inc. Profile

About Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

CEO
Dr. Jeffrey L. Stein Ph.D.
Employee
73
Address
6310 Nancy Ridge Drive
San Diego, 92121

Cidara Therapeutics, Inc. Executives & BODs

Cidara Therapeutics, Inc. Executives & BODs
# Name Age
1 Ms. Allison Lewis CCP, SPHR
Senior Vice President of People & Culture
70
2 Dr. Preetam Shah M.B.A., Ph.D.
Chief Financial Officer, Chief Business Officer & Principal Accounting Officer
70
3 Dr. Taylor Sandison
Chief Medical Officer
70
4 Dr. Jeffrey L. Stein Ph.D.
President, Chief Executive Officer & Executive Director
70
5 Mr. Shane M. Ward
Chief Operating Officer & Chief Legal Officer
70
6 Dr. Nicole Davarpanah J.D., M.D.
Senior Vice President of Translational Research & Development
70
7 Dr. Leslie Tari Ph.D.
Chief Scientific Officer
70
8 Ms. Laura A. Navalta
Senior Vice President of Clinical Operations
70
9 Dr. Kevin M. Forrest Ph.D.
Founder and Chief Strategy Officer
70

Cidara Therapeutics, Inc. Competitors